- Bidisha Gupta
View
Share
Specialty pharmacy turnaround time begins when a new prescription arrives. It runs until the medication is ready or scheduled for delivery, not necessarily until the patient’s first dose. That interval also varies widely. Across 465 accredited specialty pharmacies, URAC reported an aggregate of 12.08 business days for new prescriptions needing intervention. Clean new prescriptions came in at 5.20. That gap tells leaders where to look, even before it tells them why.
This guide is for specialty pharmacy, health-system pharmacy, and patient support leaders who own that number. It defines the measure, explains what published benchmarks can and cannot show, and maps where referrals stall. It then sets out stage-level metrics, practical fixes, and which tasks a trained support team can take on.
What Specialty Pharmacy Turnaround Time Measures
The Pharmacy Quality Alliance endorsed a standard specialty pharmacy turnaround time measure in 2021. It counts whole days from receipt of a new prescription until the drug is ready or scheduled for delivery. The result is an average for each specialty pharmacy, and a lower number means better performance.
Time to therapy, by contrast, is the broader idea. It runs from the referral to the patient’s first dose, so it also includes delivery and any injection training. Both are useful, of course. However, they answer different questions, and mixing them makes reports impossible to compare.
So, before measuring, set clock rules once. Decide whether you count business or calendar days, and when the clock pauses. For example, decide whether time waiting on a prescriber counts against the pharmacy. Then apply the same rules to every site, drug, and payer.
What Published Benchmarks Show, and What They Do Not
URAC asks accredited specialty pharmacies to report turnaround time in business days. It also separates new from refill prescriptions. In addition, it splits clean prescriptions from those needing intervention, such as prior authorization. The 2025 URAC report covers 2024 data.
| Prescription type | Aggregate (business days) | Median (business days) |
|---|---|---|
| Clean new prescriptions | 5.20 | 2.43 |
| New prescriptions requiring intervention | 12.08 | 3.74 |
| Clean refill prescriptions | 2.76 | 1.98 |
| Refill prescriptions requiring intervention | 4.51 | 2.78 |
Still, read these numbers with care. The aggregate pools every reported prescription, so pharmacies with more volume count for more. The median, by contrast, is the middle pharmacy’s result. So when the aggregate is far above the median, the typical pharmacy is much faster than the pooled figure. Some high-volume pharmacies or slow cases pull the aggregate up. Likewise, the gap between clean and intervention prescriptions shows where to investigate. It does not identify the cause of any single delay. Earlier Pharmacy Quality Alliance research found that pharmacies calculated turnaround time inconsistently. Meanwhile, a 2026 JMCP paper reports on piloting a turnaround time quality measure. Consistent definitions, in other words, are still a work in progress.
Where Referral-to-Fill Delays Occur
In practice, delays rarely come from one step. Instead, they come from handoffs, missing information, and steps that run one after another when they could overlap. In the Pharmacy Quality Alliance study, pharmacists named prior authorization and financial assistance among the main impediments. Use the framework below to investigate where your referrals stall. The actual cause and the owning team will vary by organization.
| Step | Possible cause of delay | Typical owner |
|---|---|---|
| Referral intake | Missing demographics, insurance, labs, or clinical notes | Intake team |
| Benefits investigation | Unclear pharmacy vs. medical benefit, limited distribution networks | Benefits team |
| Prior authorization | Incomplete clinical information, slow payer response, appeals | PA team with the prescriber |
| Financial assistance | Copay program or foundation enrollment started late | Financial counselors |
| Patient onboarding | Unreachable patient, consent, language barriers | Patient care team |
| First-fill scheduling | Delivery window, cold chain, injection training | Pharmacy and logistics |
Prior authorization is usually the most visible wait. A 2026 JAMA Health Forum study followed 205,896 branded prescriptions first rejected for prior authorization. Payers resolved about 35% the same day. The rest took a median of six days, and only 54% were eventually approved.
Delay also turns into lost patients, because some never start therapy. According to IQVIA, 65% of prescriptions for novel medicines launched in 2020 to 2024 went unfilled. That covers the first year. Payers rejected 49%, and patients abandoned a further 17% after approval.
How to Measure Each Stage
An overall turnaround number only shows that a problem exists. Stage-level timestamps show where it is. The measures below are suggested internal metrics, not published benchmarks. Therefore, set your own clock rules and exceptions for each one.
| Stage | Clock starts | Clock stops | What it reveals |
|---|---|---|---|
| Referral intake | Referral received | Referral complete | Delays from missing documentation |
| Benefits investigation | Investigation started | Benefits verified | Coverage verification bottlenecks |
| Prior authorization | Request submitted | Payer decision | Payer wait versus preparation time |
| Patient onboarding | First outreach | Successful contact | Contactability and coordination issues |
| Approval to first fill | Approval received | Dispensed or delivered | Delays that persist after approval |
Next, tag each slow referral with the stage, payer, drug, and handoff that held it. After a few weeks, patterns appear. Often, one payer, referral source, or missing document type explains much of the delay.
How to Reduce Delays Without Adding Pharmacists
First, run steps in parallel where you can. Where eligibility, documents, consent, and program rules allow, start benefits checks, assistance screening, and outreach alongside prior authorization. Identify dependencies early, so one pending task does not hold up the rest. That way, the team has often enrolled and scheduled the patient when approval comes.
Second, make intake complete on the first pass. For example, a referral checklist by drug and payer tells staff exactly what to request from the prescriber’s office. It also gives the office one consolidated request instead of several separate calls. Over time, the same checklist shows which offices and drugs cause the most rework.
Third, put follow-up on a schedule. In other words, each open prior authorization needs a next action and a due date. Escalate anything past its expected turnaround rather than waiting for the payer to respond.
Finally, keep the patient informed at each milestone, which reduces inbound status calls and catches problems early. Integration also shows what coordinated steps can achieve. In one health-system specialty pharmacy study, the integrated pharmacy filled oncology prescriptions in a median of five business days. Outside specialty pharmacies took nine.
Bilingual Onboarding for Specialty Patients
However, onboarding calls are not simple scheduling calls. They cover consent, insurance, financial assistance, and delivery, often for a patient facing a serious diagnosis. When a Spanish-speaking patient gets the call in English, the team misses details and calls repeat. Our bilingual call center teams run these conversations in the patient’s preferred language. Clinical counseling still goes to a pharmacist.
What to Outsource and What to Keep Clinical
Clear boundaries, above all, make extra capacity safe. Pharmacists keep anything that requires clinical judgment. By contrast, repeatable administrative work can move to trained support staff. They work in a HIPAA-compliant workflow with defined escalation rules.
| Task | Who handles it |
|---|---|
| Collecting missing referral documents | Trained support staff |
| Benefits checks and payer status follow-up | Trained support staff |
| Assistance program enrollment paperwork | Trained support staff |
| Welcome, scheduling, and delivery calls | Trained support staff |
| Clinical review, counseling, and therapy questions | Pharmacist |
| Adverse event reports and clinical concerns | Escalated to a pharmacist at once |
Before adding external support, identify which stages account for the most elapsed time. Additional administrative capacity can help when the bottleneck is missing documents, repeated status calls, benefits follow-up, or reaching patients. However, if payer decision time or clinical review drives the delay, more administrative staff alone will not fix it. In one pharmacy support case study, a dedicated nearshore team grew from 8 to 14 specialists. That raised support capacity by 75% as volumes rose.
Prior Authorization Rules That Affect Planning
Meanwhile, electronic prior authorization for pharmacy-benefit drugs is becoming standard. A 2024 Part D final rule sets the date. From January 1, 2028, prescribers, dispensers, and Part D sponsors must use NCPDP SCRIPT version 2023011. That version includes electronic prior authorization transactions. Separately, CMS proposed drug prior authorization timeframes in CMS-0062-P in April 2026. At the time of review, it was still a proposal, so check its status before planning around it. Our summary of the CMS prior authorization rule covers the medical-benefit side.
Metrics and a 90-Day Improvement Plan
Similarly, report a short set of measures weekly, by drug and payer. Compare clean and intervention referrals separately, as URAC does.
| Metric | What it tells you |
|---|---|
| Turnaround time, new prescriptions | Receipt to ready or scheduled, as PQA defines it |
| Referral to first dose | The patient’s full wait, end to end |
| Referral completeness at intake | Share of referrals with every required item on day one |
| Abandonment before first fill | Patients lost between referral and dispensing |
| Touches per referral | Calls and faxes needed to reach first fill |
Next, put the work on a 90-day plan with a clear deliverable for each phase. Start with clock definitions, because every later comparison depends on them. Then move to analysis, and only then to workflow changes.
| Phase | Deliverable |
|---|---|
| Weeks 1 to 2 | Agreed clock definitions, timestamp coverage, and baseline reporting |
| Weeks 3 to 6 | Bottleneck analysis by payer, drug, referral source, and intervention status |
| Weeks 7 to 12 | Two targeted workflow changes, compared against the baseline |
Judge the changes on median turnaround time and the share of referrals meeting an internal target. Also track referral completeness and abandonment before first fill. Where possible, separate internal processing time from time spent waiting on a payer, prescriber, or patient. That split shows which delays your team can actually control.
Losing time between referral and first fill?
Identify which administrative tasks are slowing your specialty pharmacy. SkyCom supports referral documentation, benefits follow-up, patient outreach, and scheduling through trained, bilingual, HIPAA-compliant teams on U.S. hours. Talk to us about your referral volumes, current bottlenecks, and capacity needs.
Conclusion
Specialty pharmacy turnaround time is easiest to improve once you measure it consistently. Define the clock with the PQA measure in mind, compare clean and intervention prescriptions, and timestamp each stage. Next, run benefits, assistance, and onboarding work in parallel with prior authorization. Finally, decide which administrative work a trained team can carry. For related reading, see our guides on prior authorization support, prescription abandonment, and pharmacy patient communication.
Frequently Asked Questions
What is specialty pharmacy turnaround time?
It runs from receipt of a new prescription until the drug is ready or scheduled for delivery. The Pharmacy Quality Alliance endorsed a standard measure for it in 2021.
How is turnaround time different from time to therapy?
Turnaround time usually stops when the prescription is ready or scheduled. Time to therapy runs to the patient’s first dose, so it also includes delivery and any training.
What is a good specialty pharmacy turnaround time?
It depends on the drug and payer. In URAC’s 2025 report, clean new prescriptions had a median of 2.43 business days. New prescriptions requiring intervention had a median of 3.74 business days and a much higher aggregate.
Why do some specialty prescriptions take so long?
Common causes include incomplete referrals, benefits investigation, prior authorization, financial assistance enrollment, and difficulty reaching the patient. Stage-level timestamps show which applies.
Which specialty pharmacy tasks can be outsourced?
Trained support staff can collect referral documents, run benefits checks, and follow up with payers. They can also handle assistance paperwork and scheduling calls. Pharmacists keep clinical review and counseling.
When will electronic prior authorization be required for Part D?
A 2024 final rule requires NCPDP SCRIPT version 2023011, which includes electronic prior authorization transactions, from January 1, 2028. Check current CMS guidance for updates.
